Aim of the review
=================

At present, the meaning of elevated homocysteine concentrations for cardiovascular risk is unclear. Retrospective case-control studies show a clear, strong association of hyperhomocysteinemia and elevated risk, however, in prospective observational studies, the association is less strong ([@b33]). One reason for this discrepancy can be the influence of the disease on homocysteine concentrations. Indeed, research has shown that a number of drugs frequently given to patients with CVD that might also have an influence on homocysteine.

Therefore, this review will 1) briefly summarize the epidemiological and biochemical evidence of the association between homocysteine and CVD, 2) summarize the effect of lipid-lowering drugs on homocysteine, 3) summarize the effect of anti-hypertensive drugs on homocysteine, and finally, comment on the clinical implications of drug-induced increase of homocysteine.

Link between homocysteine levels and cardiovascular disease
===========================================================

Cardiovascular diseases remain the main cause of mortality in industrialized countries and become increasingly prevalent in developing countries. The risk to develop cardiovascular disease is mainly attributable to a number of known risk factors, that are in first instance hyperlipidemia, hypertension, smoking and diabetes mellitus. However, other risk factors must also contribute to cardiovascular disease, as the primary risk factors can not explain all cases of CVD. Among other risk factors, hyperhomocysteinemia was recognized during the last decades as a preventable risk factor present in about 30% of patients with coronary heart disease ([@b8]) and in 10%--15% of the general population ([@b64]; [@b17]). The association between elevated homocysteine concentrations and coronary, cerebral or peripheral artery disease was investigated in numerous epidemiological studies with either retrospective or prospective study design. Furthermore, clinical trials are underway or have been closed to investigate whether a lowering of elevated homocysteine concentrations will reduce recurrent cardiovascular disease ([@b14]). In addition, a huge number of biochemical studies was performed to investigate the effect of homocysteine on endothelial cells, smooth muscle cells, thrombocytes, or clotting factors.

Epidemiological studies
-----------------------

In order to have an overview on the epidemiological studies conducted on the issue, several meta-analyses have been performed. The first meta-analysis was published more than 10 years ago by [@b8]), who included 27 studies relating homocysteine to arteriosclerotic vascular disease ([Table 1](#tbl1){ref-type="table"}). Most of the following meta-analyses considered more prospective trials that had been published in the meantime, and reported divergent results for retrospective studies compared with prospective studies ([Table 1](#tbl1){ref-type="table"}). Overall, retrospective studies show a stronger association of homocysteine and CVD than prospective studies. In addition, the association of homocysteine to stroke seems to be stronger than the association to coronary heart disease. Most meta-analyses calculated the odds ratios for an increase of plasma homocysteine of 5 µmol/L. However, it has to be taken into account that the standard deviation of plasma homocysteine measured in healthy populations is in the magnitude of 3--4 µmol/L. Therefore, an increase of 5 µmol/L represents a fairly large increase in homocysteine. According to this, it can be concluded, that elevated homocysteine is a significant but modest risk factor for coronary, cerebral, or peripheral artery disease ([@b83]; [@b33]).

###### 

Overview of meta-analyses on homocysteine and CVD since 1995

  Year and author                  No. of studies Included   No of retrospective/prospective studies   Main results (OR and 95% CI)
  -------------------------------- ------------------------- ----------------------------------------- --------------------------------------
  1995 Boushey                     27                        24/3                                      Hcy + 5 μmol/L:
                                                                                                       1.6 (1.4--1.7) Men, CAD
                                                                                                       1.8 (1.3--1.9) Women, CAD
                                                                                                       1.5 (1.3--1.9) Cerebrovasc.
  2000 Moller                      12                        8/4                                       Hcy \> 95th percentile:
                                                                                                       3.97 (3.07--5.12) Cerebrovasc.
  2000 Cleophas                    33                        22/11                                     elevated Hcy (no further def.)
                                                                                                       1.49 (1.33--1.67) prospective CAD
                                                                                                       1.62 (1.50--1.74) retrospect. CAD
  2002 Kelly                       14                        11/3                                      HHcy (binary variable)
                                                                                                       1.79 (1.61--2.0) Stroke
  2002 Wald                        20                        −/16                                      IHD, 8 Stroke Hcy + 5μmol/L:
                                                                                                       1.32 (1.19--1.45) IHD
                                                                                                       1.59 (1.29--1.96) Stroke
  2002 Ford                        38 CHD                    26/12                                     Hcy + 5 μmol/L
                                                                                                       1.23 (1.07--1.41) prospective
                                                                                                       1.70 (1.50--1.93) retrospective
                                   24 stroke                 17/7                                      1.58 (1.35--1.85) prospective
                                                                                                       2.16 (1.65--2.82) retrospective
  2002 Hcy Studies Collaboration   30                        IHD: 15/12                                Hcy --- 25%
                                                                                                       0.83 (0.77--0.89) prospective IHD
                                                                                                       0.67 (0.62--0.71) retrospect. IHD
                                                             Stroke: 5/8                               0.77 (0.66--0.90) prospective stroke
                                                                                                       0.86 (0.73--1.01) retrospect. stroke

**Abbreviations**: CAD, coronary artery disease; CHD, coronary heart disease; CI, confidence interval; OR, odds ratio; IHD, ischemic heart disease; Hcy, homocysteine; HHcy, hyperhomocysteinemia.

Biochemical studies
-------------------

Homocysteine exerts its atherogenic properties via several mechanisms, which have not been fully elucidated to date. In vitro studies showed that homocysteine is cytotoxic to endothelial cells, promotes the proliferation of smooth muscle cells, and leads to several interactions with platelets, clotting factors, and lipids ([@b85]; [@b78]; [@b48]). In addition, homocysteine can disrupt the folding and processing of newly synthesized proteins in the endoplasmic reticulum ([@b88]). Homocysteine can also induce oxidative stress and is able to reduce the bioavailability of nitric oxide, mechanisms leading to endothelial dysfunction.

However, since most of the results are derived from in vitro studies using supraphysiological concentrations of homocysteine, their significance to the in vivo processes of atherogenic plaque formation and disruption have to be determined.

Endothelial function
--------------------

Measurement of endothelial function offers an elegant in vivo method to study an atherogenic effect of a compound, since endothelial vasodilation of the brachial artery correlates well with the function of coronary arteries ([@b12]). It was shown in a number of studies that hyperhomocysteinemia impairs endothelial-dependent vasodilation, which is regarded as an early and preclinical sign of atherosclerosis ([@b76]; [@b13]; [@b77]). Mechanisms leading to endothelial dysfunction by hyperhomocysteinemia depend probably on the generation of reactive oxygen species, decreased bioavailability of nitric oxide (NO) and concurrent elevation of asymmetric dimethylarginine (ADMA), a strong inhibitor of the NO synthase ([@b62]; [@b6]).

Effects of anti-hyperlipidemic drugs
====================================

Hyperlipidemia is the term for a number of conditions of dysregulated lipid metabolism which require different treatment regimens. While the risk associated with elevated total cholesterol and elevated LDL-cholesterol is well investigated, the significance of elevated triglycerides, low HDL-cholesterol or elevated Lp(a) for CVD risk is less clear ([@b2]; [@b37]). Hypercholesterolemia is a primary risk factor for cardiovascular disease. Large-scale randomized trials have shown that lipid-lowering with HMG-CoA reductase inhibitors (statins) reduce relative risk for cardiovascular events or death both in primary and in secondary prevention ([@b27]). Therefore, statins are widely used for the treatment of hypercholesterolemia. Hypertriglyceridemia, however, is less well established as risk factor for cardiovascular disease. Furthermore, results of randomized clinical trials for treatment of hypertriglyceridemia have been less convincing than trials with statins ([@b79]; The DAIS investigators 2001; [@b39]). Low HDL-cholesterol is frequently associated with elevated triglycerides. Drugs of choice for the treatment of hypertriglyceridemia and low HDL-cholesterol are the fibrates which act via activating peroxisome proliferation-activated receptors α (PPAR α), nicotinic acid, or derivatives from this compound which act primarily on the adipocytes, and n3-fatty acids. All of these compounds have been investigated with respect on their effect on the homocysteine concentration, which will be summarized within this review.

Fibrates
--------

Fibric acid derivatives (fenofibrate, bezafibrate, ciprofibrate, gemfibrozil) are the drugs of choice for the treatment of hypertriglyceridemia ([@b23]). Upon treatment, plasma triglycerides may be reduced by 30%--60% and cholesterol by 20%--25%, while HDL-cholesterol will be increased ([@b10]). Fibrates represent synthetic ligands of PPAR α, leading to increased activation of genes involved in lipid metabolism and increased fatty acid metabolism ([@b23]).

The effect of fibrates on homocysteine has been investigated both in short-term studies and in long-term epidemiological studies. The long term studies have been designed with the aim of proving the protective effect of fibrates on cardiovascular risk and in subgroups, the effect on homocysteine has been studied in stored samples ([@b25]; [@b39]).

Numerous short-term studies revealed that administration of fenofibrate was associated with an elevation of homocysteine of the magnitude of 40%--50% ([@b19]; [@b45]; [@b26]; [@b5]). Ciprofibrate was less often investigated ([@b30]). These studies were all short-term studies lasting for 6--12 weeks. However, re-evaluation of randomized clinical trials with fibric acid derivatives confirmed the homocysteine increase also after longer periods: In the Diabetes Atherosclerosis Intervention Study (DAIS), 418 patients with diabetes mellitus type 2 and mild lipid abnormalities received fenofibrate (n = 207) or placebo (n = 211) for a mean period of 40 months. At baseline and at the end of the study, a coronary angiography was performed (DAIS study group 2001). Homocysteine increased in the fenofibrate group on average by 5.6 ± 6.3 µmol/L and remained unchanged throughout the study in the placebo group. Increase in homocysteine did not alter results obtained in the angiography (neither mean segment diameter, mean lumen diameter nor % stenosis). The absolute increase in homocysteine was similar over the whole range of baseline homocysteine levels, leading to higher percent increase in those with initially low homocysteine concentrations ([@b25]). Folate and cobalamin were not affected by fenofibrate treatment. In a multinational, randomised controlled trial, the FIELD study ([@b39]), 4895 patients with type 2 diabetes mellitus received 200 mg fenofibrate daily. Fenofibrate did not significantly reduce the risk of the primary outcome of coronary events. The median plasma homocysteine concentration increased about 4 µmol/L. There was a slight increase in pulmonary embolism (p = 0.022), but whether changes in homocysteine are causal for embolism in this study is unknown.

Administration of bezafibrate also leads to an increase of total homocysteine in short-term studies, as shown by our group ([@b19]) and others ([@b38]). The homocysteine increase was somewhat lower than the increase observed after fenofibrate, and was about 20%--35%.

Some conflicting data are available on the effect of gemfibrozil on homocysteine. Gemfibrozil differs in some aspects from beza- or fenofibrate, as it does not involve PPAR α activation. In a study of our group, we did not observe any effect of gemfibrozil on plasma homocysteine concentrations in 22 hyperlipidemic men ([@b86]). In contrast, a recent re-evaluation of the Lopid Coronary Angiography Trial (LOCAT), a homocysteine increase of 18% was observed in 178 patients treated with gemfibrozil for 16 months while no change of homocysteine was observed in the placebo group (n=184) ([@b75]). Differences between studies are the administered dose of gemfibrozil (900 mg versus 1200 mg), study duration (6 weeks versus 16 months) and sample size (n = 22 vs n = 178).

In conclusion, it is evident that the elevation of homocysteine by fibric acid derivatives is a class effect which is especially observed after fenofibrate. Mechanisms responsible for this effect may be 1) effects of fibrates on the creatine-creatinine pathway ([@b34], [@b35]; [@b9]; [@b50]), 2) the downregulation of the renal cyclo-oxygenase enzyme (COX-2), thus inhibition of synthesis of renal vasodilating prostaglandins ([@b89]; [@b90]; [@b42]), and 3) a yet unknown effect of PPAR α activation on homocysteine metabolism ([@b47]; [@b51]).

Concerning creatine-creatinine metabolism, it must be noted that both fenofibrate and bezafibrate cause increases of serum creatinine concentrations, but obviously not due to an alteration of the glomerular filtration rate ([@b34]). Obviously, fenofibrate induces an increased creatine turnover rate. However, an increase in creatine turnover may also cause an increase of homocysteine since the methyl group of creatine is donated by S-adenosylmethionine, rendering S-adenosylhomocysteine and thus homocysteine ([@b61]).

Downregulation of the renal COX-2 enzyme system by PPAR α activation leads to decreased synthesis of vasodilating prostaglandins and may then reduce glomerular filtration rate. The action of these vasodilating prostaglandins is especially important in patients with impaired renal function ([@b42]).

Recently, it has been shown that the homocysteine increasing effect of fibrates depend on the activation of PPAR α in rodents ([@b47]; [@b51]). Fenofibrate mixed into the diet caused a doubling of homocysteine concentration in wild-type mice, while in PPAR α deficient mice, no change of homocysteine concentrations was observed. In a similar experiment, PPAR α-knock out mice had initially slightly lower homocysteine concentrations than wild-type mice, and there was no increase in homocysteine in the knock-out mice after 2 weeks administration of fenofibrate at a dose of 100 mg/kg. In rats, fenofibrate caused an increase of homocysteine by more than 80% ([@b47]; [@b51]). In contrast, [@b74]) did not find any increase in homocysteine after treatment with rosiglitazone. Rosiglitazone, a novel class of antidiabetic drugs, is an agonist of PPAR γ receptors.

At present, there are no data suggesting an effect of fibrates on folate or cobalamin metabolism. In the short-term studies, no effect of fibrates was observed on vitamin levels ([@b19], [@b17]; [@b5]; [@b86]; [@b57]). Additionally, there was no chance in folate or cobalamin levels during the DAIS study ([@b25]). Furthermore, macrocytic anemia or other signs of vitamin deficiency are not associated with long-term treatment with fibrates.

In healthy populations, vitamin supplementation with folic acid and/or cobalamin can reduce circulating homocysteine concentrations effectively by about 25% ([@b32], 2005). Therefore, addition of vitamins to fenofibrate may be an option to decrease homocysteine concentrations during fibrate treatment. This was investigated in studies using folic acid, vitamin B12 and vitamin B6 in nutritional doses ([@b17]) or using a high dose of folic acid (5--10 mg) ([@b73]; [@b55]; [@b54], [@b53]). The uniform result of these studies is that vitamin or folic acid addition to fenofibrate can reduce the increase of plasma homocysteine, but still a small, significant increase of homocysteine can be observed, ranging from 6% to 20%. Other fibrates have not been tested in conjunction with vitamins. Recently, other effects of folic acid added to fenofibrate have been reported: the combination of fenofibrate and folic acid reduced oxidized LDL-cholesterol and von Willebrand factor and thrombomodulin, biochemical markers of endothelial function ([@b53]). However, these results have been obtained in a small study in 18 volunteers and await confirmation in other studies.

HMG-CoA reductase inhibitors (statins)
--------------------------------------

Statins are widely used for the prevention of cardiovascular disease through the reduction of total cholesterol and especially LDL-cholesterol. With respect to homocysteine, they have mainly been used as comparison to a fibrate arm during short-term studies ([@b16]; [@b56]; [@b70]; [@b57]). No study directly compared different statins. In the prospective AFCAPS/TexCAPS trial, a small reduction of homocysteine during one year of treatment with lovastatin was observed ([@b68]), however, this finding was statistically significant, but the biological meaning of homocysteine reduction of −0.4 µmol/L may be questioned.

From these and other studies, it can be concluded that statins do not influence homocysteine concentrations significantly. Furthermore, the concurrent administration of statins and vitamins was investigated in a pilot study of the SEARCH trial ([@b52]), revealing that there is obviously no effect of the statin component, as the reduction of plasma homocysteine levels was similar in the vitamin group and the vitamin plus statin group.

Nicotinic acid (niacin)
-----------------------

The cholesterol-lowering effect of high doses of nicotinic acid was recognized as early as 1955 ([@b1]). Nicotinic acid lowers total cholesterol, but is at present re-considered since it is also able to increase the protective HDL-cholesterol concentration ([@b66]). While the physiological dose of the vitamin is about 20 mg per day, the lipid-lowering effect requires administration of 1.5--3 g of nicotinic acid ([@b43]). A first analysis in humans whether niacin may also influence homocysteine was made in the Arterial Disease Multiple Intervention Trial (ADMIT). Homocysteine was measured in subgroups treated either with niacin (n = 24) or placebo (n = 22). After 18 and 48 weeks of treatment with niacin, average homocysteine levels were 21.1 and 19.9 µmol/L in the niacin group and 11.5 and 11.6 µmol/L in the placebo group, respectively. Unfortunately, no vitamin levels during follow-up were presented ([@b24]). In animal studies, high doses of niacin were associated with lower levels of vitamin B6 and increased homocysteine concentrations ([@b4]). Addition of vitamin B6 corrected the hyperhomocysteinemia. Since nicotinic acid is excreted in the methylated form, administration of this drug increases the total methyl demand substantially. Thus, formation of S-adenosylhomocysteine from S-adenosylmethionine is increased. Single cases of drastically increased homocysteine concentrations after niacin administration have been reportet ([@b84]). There is no study in humans that considered vitamin B6 during niacin therapy. On the other hand, a recent study which compared the effect of simvastatin or simvastatin plus niacin (2 × 1000 mg/d) did not observe a higher frequency of hyperhomocysteinemia in the simvastatin plus niacin group (any homocysteine \> 15 µmol/L, measured bimonthly for 38 months: 4% in the simvastatin group versus 9% in the combination group, p = 0.191). However, this report did not provide means or median values ([@b92]).

Thus, at present, the effect of niacin on homocysteine and related vitamins in humans is unclear, although there is some evidence that niacin may raise homocysteine. Further studies are needed to clarify this issue, especially when keeping in mind the rising prescription of niacin.

n3-fatty acids
--------------

N3-fatty acids in relatively high doses (2--6 g/d) are used in the treatment of severe hypertriglyceridemia. One of the very early studies on homocysteine reported that administration of n3 fatty acids reduces plasma homocysteine ([@b65]). Since then, a number of studies has been published on this association, however, with conflicting results. There are studies that report an increase of homocysteine after administration of fish oil or pure n3-fatty acids ([@b7]; [@b67]), compared with studies that observed no effect on homocysteine ([@b28]), or even a decrease of homocysteine after administration of fish oil ([@b65]; [@b29]; [@b91]). At a glance, the different results cannot be attributed to differences in study design, fatty acids used or exclusion criteria of study subjects. Thus, the effect of n3-fatty acids on homocysteine cannot be uniformly described at present. However, it has to be kept in mind that the effects of n3 fatty acid on homocysteine described have been small, ranging from increase by 15%--20% or decrease in the same magnitude. Therefore, chance findings are also likely. In addition, some doubts to the data may be allowed since there is no obvious hypothesis on the mechanism by which n3-fatty acids would alter homocysteine levels. One link may be vitamin B6 which serves as coenzyme both in the homocysteine-transsulfuration pathway but also as cofactor of the d6 desaturase which is involved in PUFA metabolism. Recently, in a rat study an elevated homocysteine concentration was measured in vitamin B6-deficient animals compared with animals with normal vitamin B6. Even more interestingly, significantly higher homocysteine levels were observed in vitamin B6 deficient animals receiving diet high in polyunsaturated fatty acids (PUFA), compared with vitamin B6 deficient animals receiving a diet with saturated fatty acids ([@b11]). It is not known at present, whether these results are also applicable in humans. Unfortunately, studies on PUFA supplementation in humans did not provide vitamin B6 levels at all. Obviously, in rats, homocysteine is closer related to vitamin B6 metabolism than in humans ([@b4]). Further studies are necessary to clarify this issue.

Conclusion--lipid lowering drugs
--------------------------------

Homocysteine is increased by administration of fibric acid derivatives. Statins do not influence homocysteine levels, while the effect of nicotinic acid and n3-fatty acids is less clear. Concurrent vitamin administration with fibrates can attenuate the homocysteine increase substantially.

Anti-hypertensive drugs
=======================

Drug treatment strategies to lower blood pressure vary widely throughout the world ([@b63]). Many studies have recently revealed that homocysteine is positively correlated with blood pressure, especially the systolic component ([@b64]; [@b36]; [@b72]); however, this association is not evident in other studies ([@b82]). The effects of different antihypertensive agents on plasma homocysteine levels have not been tested extensively. Recent studies have reported associations between diuretic drug therapy for the treatment of hypertension with homocysteine elevations ([@b64]). Data from the Framingham Offspring Study showed a highly significant positive association between the use of antihypertensive medication and homocysteine concentrations ([@b36]). Such treatment-associated increases in homocysteine may be a cause for concern if they were to reduce the cardio-protective effects of lowering of blood pressure.

Diuretics
---------

Recent studies have reported that use of diuretics as an antihypertensive drug is associated with increased levels of homocysteine. [@b60]) analyzed plasma concentrations of homocysteine, vitamins B6 and B12, and RBC folate in 17 hypertensive patients receiving long-term diuretic therapy and 17 hypertensive patients not taking diuretics The mean serum homocysteine concentration of patients taking diuretics (17.9 ± 1.7 µmol/L) was significantly higher than for patients not taking diuretics (10.3 ± 1.0 µmol/L). The mean RBC folate concentration for patients taking diuretics (281 ± 18 ng/mL) was significantly lower than that for patients not taking diuretics (431 ± 29 ng/mL). Serum vitamin B6 and vitamin B12 concentrations were not significantly different between the two groups. It has been known for many years that diuretics can cause a depletion of water-soluble vitamins ([@b59]), although vitamin deficiency is not a common side effect of long-term diuretic use.

In a small trial of 27 patients assigned to treatment with either hydrochlorothiazide (HCT) or an ACE inhibitor, [@b87]) measured homocysteine, creatinine, folate, vitamins B6 and B12 before and after 4--6 weeks of treatment. HCT raised homocysteine concentrations by 28%, creatinine by 12% and decreased folate levels nonsignificantly by 26%. The underlying mechanism for the increase in homocysteine was attributed to a concomitant deterioration of renal function. The magnitude of the increase in homocysteine after HCT may be clinically relevant if this increases cardiovascular risk ([@b8]) and may counteract the desired cardiovascular protection conferred by lowering blood pressure. The extent to which the changes in homocysteine may explain the discrepant results on risk of coronary heart disease associated with differences in blood pressure mediated by HCT use ([@b41]) is unclear. Possible adverse effects of HCT have been chiefly attributed to increases in LDL-cholesterol and glucose or hypokalaemia ([@b21]), but increases in homocysteine may now be added to this side effect profile of HCT therapy.

Beta blockers
-------------

[@b44]) showed in a preliminary study, that metoprolol therapy significantly decreased homocysteine levels both in the first and fifth months of treatment. Two years later, [@b3]) investigated in a prospective study the effects of beta-blocker therapy on homocysteine levels in patients with hypertension. 120 patients with newly diagnosed hypertension were enrolled. All patients received metoprolol succinate 100 mg/day initially. If blood pressure was above normal on the 15th day of follow-up, the metoprolol dosage was doubled. Homocysteine levels decreased significantly by the end of the fourth month when compared with basal values (13.5+/--4.5 µmol/L vs 12.4+/--4.9 µmol/L; p = 0.001). There was no relation between homocysteine level and blood pressure control. There was a significant decrease in homocysteine levels in the women treated in this study (p = 0.001); however, this effect was absent in men (p =0.185). [@b71]) studied hypertensive patients with coronary and cerebral atherothrombosis and discovered that homocysteine levels were lower in patients who were taking beta-blockers.

Other anti-hypertensive drugs and conclusion
--------------------------------------------

It is unclear whether other anti-hypertensive drugs, such as ACE inhibitors or calcium-channel blockers influence homocysteine concentrations since their effects have not been widely studied. In summary, most of the available evidence suggests that blood pressure lowering therapy with diuretics is associated with an increase of plasma homocysteine concentrations.

Implications and conclusions: Is drug-induced hyperhomocysteinemia important?
=============================================================================

Recently, results of the first randomized clinical trials on homocysteine lowering by vitamins in secondary prevention have been become public ([@b69]; [@b49]; [@b46]; [@b81]). Results are, however, not encouraging that lowering homocysteine by vitamins will be effective in reducing cardiovascular morbidity or mortality in secondary prevention. However, even in the VISP study ([@b81]), a high baseline homocysteine concentration was associated with worse outcome. Therefore, at present, the significance of elevated homocysteine due to whatever cause is unclear.

Current evidence shows that a clear, uniform homocysteine increase can be expected in patients treated with fibrates (fenofibrate or bezafibrate) and with thiazides ([Table 2](#tbl2){ref-type="table"}).

###### 

Effect of fibrates on homocysteine concentration (mean ± standard deviation, unless otherwise noted)

  Study         N     treatment Fenofibrate                 tHcy before   tHcy after    \% change                                           P
  ------------- ----- ------------------------------------- ------------- ------------- --------------------------------------------------- ------------------------------------------
  [@b16]        29    200 mg/d,12 weeks                     11.4 ± 3.5    16.6 ± 5.2    \+ 56 %                                             \<0.001
  [@b19]        10    200 mg/d, 6 weeks                     13.1          20.0          \+ 44 (.8 ± 85) %[b](#tf2-2){ref-type="table-fn"}   [a](#tf2-1){ref-type="table-fn"}\<0.001
  [@b45]        8     according to renal failure, 8 weeks   15.1          21.8          \+ 44 %                                             [a](#tf2-1){ref-type="table-fn"}p = 0.03
  [@b26]        29    200 mg/d, 6 months                    12.3 ± 3.9    16.2 ± 4.6    \+ 32 %                                             \<0.001
  [@b5]         20    200 mg/d, 8 weeks                     10.3 ± 3.3    14.1 ± 3.8    \+ 37 %                                             \<0.001
  [@b17]        25    200 mg/d, 6 weeks                     10.7          14.0          44 ± 47 %[b](#tf2-2){ref-type="table-fn"}           [a](#tf2-1){ref-type="table-fn"}\<0.001
  [@b86]        22    200 mg/d, 6 weeks                     10.7          14.4          \+ 35 %                                             [a](#tf2-1){ref-type="table-fn"}\<0.001
  [@b73]        11    200 mg/d, 9 weeks                     12.3 ± 3.2    19.1 ± 7.2    \+ 55 %                                             \<0.001
  [@b56]        15    200 mg/d, 10 weeks                    12.4 ± 2.7    16.9 ± 3.7    \+ 36 %                                             \<0.001
  [@b55]        19    200 mg/d, 65 ± 18 days                11.5 ± 3.0    17.5 ± 6.5    \+ 52 %                                             not provided
  [@b54]        24    200 mg/d, 3 months                    10.0 ± 2.9    14.2 ± 2.9    \+ 42 %                                             not provided
  [@b57]        22    200 mg/d, 12 weeks                    10.3 ± 3.3    14.2 ± 3.6    \+ 38 %                                             \<0.001
  [@b25]        418   200 mg/d, 3 years                     11.0 ± 5.6    16.5 ± 10.7   \+ 55 %                                             \<0.001
  DAIS-Study                                                                                                                                
                      **Bezafibrate**                                                                                                       
  [@b19]        10    400 mg/d, 6 weeks                     11.9          15.5          +17 (.14 .65) %[b](#tf2-2){ref-type="table-fn"}     [a](#tf2-1){ref-type="table-fn"}p = 0.02
  [@b38]        16    400 mg/d, 6 weeks                     11.9 ± 2.1    14.1 ± 2.9    \+ 18 %                                             \<0.001
  [@b30]        12    400 mg/d, 6 weeks                     8.2 ± 2.3     6.8 ± 1.4     −17 %                                               p = 0.22
                      **Ciprofibrate**                                                                                                      
  [@b30]        26    100 mg/d, 12 weeks                    6.8 ± 1.8     10.6 ± 4.3    \+ 56 %                                             \<0.0001
                      **Gemfibrozil**                                                                                                       
  [@b86]        22    900 mg/d, 6 weeks                     12.9          12.4          −4 %                                                [a](#tf2-1){ref-type="table-fn"}NS
  [@b75]                                                                                                                                    
  LOCAT-Study   395   900 mg/d, 16 months                   12.6          14.1          \+ 11.9%                                            [a](#tf2-1){ref-type="table-fn"}\<0.0001

**Notes**: Median;

calculated from individual data.

**Abbreviations**: ACE inhibitor, angiotensin-converting enzyme inhibitor; BIP, bezafibrate Infarction Prevention; CAD, coronary artery disease; CI, confidence interval; CVD, cardiovascular disease; DAIS, Diabetes Atherosclerosis Intervention Study; FIELD, Fenofibrate Intervention and Event Lowering in Diabetes; GFR, glomerular filtration rate; FA, folic acid; HCT, hydrochlorothiazide; LOCAT, Lopid Coronary Angiography Trial; MTHFR, methylenetetrahydrofolate reductase; PPARα, peroxisome-proliferation activated receptor alpha; PUFA, polyunsaturated fatty acids; RR, relative risk; homocysteine, total homocysteine.

###### 

Lipid-lowering and anti-hypertensive drugs that elevate homocysteine

  Drug                      Effect on homocysteine                                      Suggested mechanisms                                           Evidence from
  ------------------------- ----------------------------------------------------------- -------------------------------------------------------------- -----------------------------------------------------------------------------------
  Fibric acid derivatives   increase of homocysteine:                                   reduction of glomerular function                               Human studies, cross-sectional and clinical trials mechanistic studies in rodents
                            \+ 40% fenofibrate                                          increased creatin/creatinine                                   
                            +20% bezafibrate                                            metabolism                                                     
                            \+ 20% gemfibrozil                                          PPARα-activation                                               
  Niacin                    increase of fasting                                                                                                        
                            homocysteine, amount unclear                                effect on vitamin B6 metabolism increased methylation demand   Human studies, mechanistic studies in rodents
  Diuretics                 increase of fasting homocysteine +20% hydrochlorothiazide   decreased glomerular filtration rate                           Human studies, cross-sectional and one clinical trial

For these drugs, the increase in homocysteine has been demonstrated in both observational studies and in clinical trials. In the case of fibrates, it was shown that addition of vitamins can reduce the drug induced hyperhomocysteinemia. There is now also a study that suggests beneficial effects of the added folic acid on the endothelium and on anti-oxidative status ([@b53]). Whether the homocysteine increase is responsible for non-significant results of prospective randomized trials with fenofibrate in secondary prevention can only be speculated at present.

The evidence for a homocysteine increase associated with other lipid lowering drugs is less convincing. The discrepant results observed for niacin and n-3 fatty acids questions about whether these drugs really influence plasma homocysteine. There is a need for more data on niacin and homocysteine and fish oil and homocysteine, also with respect to vitamin B6, which might be an important confounder that has not been rewarded until now in humans.

It has to be taken into account that the relative risk for cardiovascular events associated with an increase of homocysteine are generally modest ([Table 1](#tbl1){ref-type="table"}). Therefore, it does not seem to be justified to discontinue treatment with thiazides or fibrates because of the adverse effects on homocysteine concentrations. Physicians and their patients should be informed about the possibility of combining these drugs with low doses of folic acid, vitamin B12 and B6 in order to enable them to an informed decision.
